Page 4 - Johnson Amp News Today

Wall Street's early gains Friday moderated after a hot jobs growth number and in-line wage inflation.

Johnson & Johnson to buy Shockwave Medical for $12.5B, expanding heart device portfolio. Deal, J&Js largest since Abiomed acquisition, includes shockwave tech for heart diseases. Deal expected to close mid-2024.

The pharmaceutical firm said the acquisition will boost its portfolio for treating two common forms of heart disease.

Drug major Johnson & Johnson (JNJ) announced Friday its agreement to acquire Shockwave Medical, Inc. (SWAV) for $335.00 per share in cash. The enterprise value of the deal is around $13.

During the CNBC Investing Club's Morning Meeting on Friday, Jim Cramer discussed notable stock moves outside the Club's portfolio.

Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.

Med-tech powerhouse Johnson & Johnson made a bold bid to bolster its interventional cardiology holdings with the news on April 5 that it is acquiring Shockwave Medical Inc. for approximately $13.1 billion including cash acquired. The $335 per share cash price represents a more than 5% premium to Shockwave’s (Nasdaq: SWAV) April 4 closing price and a more than 17% premium to the stock price prior to the Wall Street Journal report last week about the rumoured deal.

The agency faulted the device maker for delayed notice of mounting complications, citing increasing reports of how use of the device perforated the walls of the heart.

The Food and Drug Administration has shared updated warnings concerning a heart pump that has led to the death of dozens of people.

The healthcare giant could soon acquire Shockwave Medical